Updated on 4 November 2026
In vivo sensing of functional microbiome activity
Scientific director at imec
Wageningen, Netherlands
About
We are developing a novel in-vivo sensing approach to measure functional microbiome activity directly in-vivo. The sensor uses genetically engineered mucins with predefined glycan structures as enzymatic substrates. Enzymatic removal of these glycan structures generates a measurable response that reflects localized microbial enzymatic activity.
This approach could provide functional information beyond conventional taxonomic microbiome profiling and enable new microbiome biomarkers and diagnostic tools. While the initial focus is on microbiomes associated with mucosal tissues, such as the gut microbiome, the principle could be extended to other microbiome environments, including the skin microbiome.
We are particularly interested in partners developing prebiotics, probiotics, postbiotics, medical foods and nutritional interventions, as well as organizations working on healthy aging and gut or skin microbiome applications. We aim to explore how functional microbiome sensing can support the development, validation and personalization of microbiome-targeted interventions.
Topic
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
Organisation
Similar opportunities
Project cooperation
Microbiome-based therapeutic strategies against antimicrobial-resistant pathogens
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
Iris Menendez
Project manager at Microviable Therapeutics
Oviedo, Spain
Project cooperation
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Ayse Caner
Professor of Basic Oncology and Parasitology | Ege University, Türkiye at Ege University, Faculty of Medicine
izmir, Türkiye
Project cooperation
Microbiome biomarker partner for AI-driven NCD prediction
- Partner seeks Consortium/Coordinator
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Sofia Fegatelli Leonova
Scientific Project Coordinator & Business Development at REM Analytics SA
Monthey, Switzerland